Last updated on: 7/10/2017 | Author: ProCon.org

Bertha Madras, PhD Biography

Title:
Professor of Psychobiology in the Department of Psychiatry at Harvard Medical School
Position:
Con to the question "Should Marijuana Be a Medical Option?"
Reasoning:

“The well-funded movement to medicalize marijuana spreading across our nation calls out for caution and restraint. Activists claim that marijuana is a safe medicine but de facto, it is evolving into a gateway for marijuana legalization. The claim conflicts with current science, with intelligent public health policy, with rigorous standards of the drug approval process, and with best practices of medicine.”

“A Blunt Force to Crush Floridians’ Opposition to Marijuana,” Sunshine State News, Mar. 2, 2016

Theoretical Expertise Ranking:
    Experts
Individuals with MDs, PhDs, JDs, or equivalent advanced degrees in fields relevant to medical marijuana. Also top-level government officials (such as foreign leaders, US presidents, Founding Fathers, Supreme Court Justices, members of legislative bodies, cabinet members, military leaders, etc.) with positions relevant to medical marijuana issues.
Involvement and Affiliations:
  • Member, President’s Commission on Combating Drug Addiction and the Opioid Crisis, June 2017-present
  • Psychobiologist, Division of Alcohol and Drug Abuse, McLean Hospital, May 2014-present
  • Research Associate, Massachusetts General Hospital, Jan. 2010-present
  • Professor of Psychobiology, Department of Psychiatry, Harvard Medical School, Apr. 1986-present
  • Deputy Director for Demand Reduction, White House Office of National Drug Control Policy, Apr. 2006-2008
  • Recipient, NIDA Public Service Award
  • Recipient, NIH MERIT Award
  • Recipient, American Academy Addiction Psychiatry Founders’ Award
  • Recipient, Mariam Hirschman Award
  • Post-doctoral Fellow, Massachusetts Institute of Technology, 1967-1969
Education:
  • MA, Harvard University, 1999
  • PhD, Tryptophan and Hallucinogen Pharmacology, McGill University, 1967
  • BSc, Biochemistry, McGill University, 1963
Other:
  • None found
Quoted in:
  1. Should Marijuana Be Reclassified as a Schedule II or III Drug?